Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission

Full Text View 

This study is not yet open for participant recruitment.

Verified November 2013 by Roswell Park Cancer Institute

Sponsor:

Roswell Park Cancer Institute

Collaborator:

National Cancer Institute (NCI)

Information provided by (Responsible Party):

Roswell Park Cancer Institute

ClinicalTrials.gov Identifier:

NCT01982487

First received: November 6, 2013

Last updated: NA

Last verified: November 2013

History: No changes posted